Six-year NATALEE data at #ESMO2026: adjuvant ribociclib plus an NSAI reduced the risk of death by 19% vs endocrine therapy alone in HR+/HER2− early breast cancer. Company-reported;

MedShr· @medshronline · X·2026-10-24 23:15· 14 小时前评分70

正文 · 原文

Six-year NATALEE data at #ESMO2026: adjuvant ribociclib plus an NSAI reduced the risk of death by 19% vs endocrine therapy alone in HR+/HER2− early breast cancer. Company-reported; full publication awaited.

#BreastCancer #Oncology #MedTwitter

63 浏览 · 2 赞 · 0 转发 · 0 回复

会议摘要

LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

来源：MedShr · x.com